Pre-Surgery Durvalumab and Tremelimumab in Breast Cancer Patients | Oncotarget



March 25, 2024

  • Share
  • Oncotarget published this trending research paper on March 19, 2024 in Volume 15, entitled, Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II–III breast cancer” by researchers from the Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX; Department of Immunology, University of Texas MD Anderson Cancer Center, Houston, TX; Department of Breast Imaging, University of Texas MD Anderson Cancer Center, Houston, TX; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX; Department of Surgery, Division of Breast Surgery, Brigham and Women’s Hospital, Boston, MA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA; Harvard Medical School, Boston, MA. DOI - Correspondence to - Haven R. Garber - Abstract A clinical trial was conducted to assess the feasibility of enrolling patients with Stage II or III hormone receptor positive (HR+)/HER2-negative breast cancer to pre-operative dual PD-L1/CTLA-4 checkpoint inhibition administered prior to neoadjuvant chemotherapy (NACT). Eight eligible patients were treated with upfront durvalumab and tremelimumab for two cycles. Patients then received NACT prior to breast surgery. Seven patients had baseline and interval breast ultrasounds after combination immunotherapy and the responses were mixed: 3/7 patients experienced a ≥30% decrease in tumor volume, 3/7 a ≥30% increase, and 1 patient had stable disease. At the time of breast surgery, 1/8 patients had a pathologic complete response (pCR). The trial was stopped early after 3 of 8 patients experienced immunotherapy-related toxicity or suspected disease progression that prompted discontinuation or a delay in the administration of NACT. Two patients experienced grade 3 immune-related adverse events (1 with colitis, 1 with endocrinopathy). Analysis of the tumor microenvironment after combination immunotherapy did not show a significant change in immune cell subsets from baseline. There was limited benefit for dual checkpoint blockade administered prior to NACT in our study of 8 patients with HR+/HER2-negative breast cancer. Sign up for free Altmetric alerts about this article - Subscribe for free publication alerts from Oncotarget - Keywords - cancer, breast cancer, ER positive, immunotherapy, neoadjuvant chemotherapy, tumor microenvironment About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit and connect with us: Facebook - X - Instagram - YouTube - LinkedIn - Pinterest - Reddit - Spotify - Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

    Analytical TechniquesCancer ResearchDrug DiscoveryImmunology

    Keep up to date with all your favourite videos and channels.

    Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.